Please login to the form below

Not currently logged in
Email:
Password:

Stallergenes

This page shows the latest Stallergenes news and features for those working in and with pharma, biotech and healthcare.

Merck gets US green light for allergy immunotherapy

Merck gets US green light for allergy immunotherapy

Grastek is the second allergy immunotherapy (AIT) product to be cleared for marketing in the US after Stallergenes' Oralair, which was approved last month.

Latest news

  • FDA backs a brace of allergy immunotherapies FDA backs a brace of allergy immunotherapies

    FDA backs a brace of allergy immunotherapies. Merck &Co and Stallergenes win drug approvals in US. ... Meanwhile for Stallergenes - with annual sales of around 250m - the upside could be significant.

  • Inducing immunity

    Hot on the heels of Grazax is Stallergenes' Oralair Grasses, which is expected to be launched in Europe in 2007.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Stallergenes appoints Christian Chavy CEO Stallergenes appoints Christian Chavy CEO

    Stallergenes appoints Christian Chavy CEO. He will replace Roberto Gradnik at the end of this month. ... Christian Chavy has been appointed CEO of French biopharmaceutical company Stallergenes and will take over from Roberto Gradnik at the end of this

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics